Invest-to-own: Biogen backs Ataxion Series A
This article was originally published in Scrip
Executive Summary
Atlas Venture and Biogen Idec funded a $17m Series A funding round for Ataxion in an invest-to-own structure that gives Biogen an option to buy the startup company if its pan-ataxia drug candidate successfully completes a Phase I clinical trial.